390- 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis- a retrospective cohort study

Home 390- 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis- a retrospective cohort study

390- 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis- a retrospective cohort study

March 15, 2022 Posted by Tim Braun

View Reference

U.S. and International Patents and Patents Pending. © 2025 Swan Valley Medical, Incorporated. All Rights Reserved. T-SPeC® and the Swan icon are registered trademarks of Swan Valley Medical, Incorporated.